Gambaran Asthma Control Test (ACT) dan Faal Paru pada Pasien Asma di RSUD Tanjungpura

Abstract

Background : Asthma is a chronic inflammatory disease of the airways associated with bronchial hyperresponsiveness and reversible airflow obstruction which generally affects 1-18% of the population. The main goals of effective management are achieving optimal control and prevention of serious exacerbations and impaired lung function. Tools for monitoring asthma control include assessing the frequency and severity of symptoms (patient/parent reports or through specific scores using the Asthma Control Test) and the use of objective measures such as spirometry and peak expiratory flow (PEF) to assess lung function. Spirometry measures how much a person inhales or exhales the maximum volume of air measured as a function of time. PEF measurement can be used to document the variability of bronchial obstruction in asthma even if the PEF is not related to the FEV1 value. Objective: To find out the description of the Asthma Control Test (ACT) and lung function in Asthma Patients at Tanjungpura Hospital. Methods: This research was conducted in an ambitious cohort with an observational descriptive design starting from March 2023 until the number of samples was fulfilled. Data in the form of asthma symptoms based on ACT, spirometry results and APE results were collected by interviews, medical records and direct data collection. The results of the data were analyzed univariately to see an overview of the Asthma Control Test (ACT) and lung function. Results: Most patients were female (64.8%) aged 18-60 years (83.3%), with the majority working as housewives (46.2%). Patients with moderate restriction were the most common (59.3%), followed by patients with moderate obstruction (46.3%). Moderate persistent asthma was found in 50% of patients. Conclusion: The use of salmeterol xinafoate and fluticasone propionate proved to be effective in asthma management, improving lung function, controlling symptoms, and improving patients' quality of life. The combination of salmeterol xinafoate and fluticasone propionate is safe and well tolerated, even at multiple doses for short term, suitable for a wide range of patients including children.